{"nctId":"NCT01126190","briefTitle":"Neugranin in Breast Cancer Participants Receiving Doxorubicin/Docetaxel","startDateStruct":{"date":"2010-06-30","type":"ACTUAL"},"conditions":["Chemotherapy-induced Neutropenia"],"count":381,"armGroups":[{"label":"Double-Blind Phase: Pegfilgrastim","type":"ACTIVE_COMPARATOR","interventionNames":["Biological: Pegfilgrastim","Drug: Chemotherapy"]},{"label":"Double-Blind Phase: Neugranin 40 mg","type":"EXPERIMENTAL","interventionNames":["Biological: Neugranin","Drug: Chemotherapy"]},{"label":"Open-Label Phase: Neugranin 40 mg","type":"EXPERIMENTAL","interventionNames":["Biological: Neugranin","Drug: Chemotherapy"]}],"interventions":[{"name":"Neugranin","otherNames":["Balugrastim"]},{"name":"Pegfilgrastim","otherNames":["Neulasta"]},{"name":"Chemotherapy","otherNames":["Doxorubicin/Docetaxel"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Breast cancer participants scheduled to receive the AT regimen (doxorubicin/ docetaxel)\n\nExclusion Criteria:\n\n* Participants may have received no more than 1 prior chemotherapy regimen (including adjuvant therapy if given within the last 12 months)","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Double-Blind Phase: Duration of Severe Neutropenia in Cycle 1","description":"Severe neutropenia was defined as Grade 4 neutropenia (absolute neutrophil count \\[ANC\\] \\<0.5 x 10\\^9/liter \\[L\\]). The duration of severe neutropenia was calculated by cycle as the number of days from the first day in which the ANC fell below 0.5 x 10\\^9/L after beginning a chemotherapy cycle until the participant had an ANC ≥0.5 x 10\\^9/L within the cycle.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.0","spread":"1.08"},{"groupId":"OG001","value":"1.1","spread":"1.13"}]}]}]},{"type":"SECONDARY","title":"Double-Blind Phase: Number of Participants With Febrile Neutropenia","description":"Febrile neutropenia was defined as an imputed or observed ANC \\<0.5 x 10\\^9/L and body temperature \\>38.5 degrees celsius (°C) occurring on the same day and for more than one hour (axillary measurement). Number of participants with febrile neutropenia over all cycles (Cycles 1 to 4) has been reported.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4","spread":null},{"groupId":"OG001","value":"2","spread":null}]}]}]},{"type":"PRIMARY","title":"Open-Label Phase: Duration of Severe Neutropenia in Cycle 1","description":"Severe neutropenia was defined as Grade 4 neutropenia (ANC \\<0.5 x 10\\^9/L). The duration of severe neutropenia was calculated by cycle as the number of days from the first day in which the ANC fell below 0.5 x 10\\^9/L after beginning a chemotherapy cycle until the participant had an ANC ≥0.5 x 10\\^9/L within the cycle. There was no planned statistical analysis for the open-label phase arm.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.0","spread":"1.03"}]}]}]},{"type":"SECONDARY","title":"Open-Label Phase: Number of Participants With Febrile Neutropenia","description":"Febrile neutropenia was defined as an imputed or observed ANC \\<0.5 x 10\\^9/L and body temperature \\>38.5 °C occurring on the same day and for more than one hour (axillary measurement). Number of participants with febrile neutropenia over all cycles (Cycles 1 to 4) has been reported.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":7,"n":150},"commonTop":["Alopecia","Nausea","Neutropenia","Asthenia","Leukopenia"]}}}